Amgen Boosts Pipeline, Adds SHPT Drug in $315M KAI Buy
By Catherine Shaffer
Wednesday, April 11, 2012
Wowed by stunning Phase IIa results for nephrology candidate KAI-4169, Thousand Oaks, Calif.-based Amgen Inc. tendered an offer of $315 million in cash to buy KAI Pharmaceuticals Inc., of San Francisco.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.